Newpathmolecular
2 known investors
New Path Molecular develops drug conjugates targeting phosphatidylserine on cancer cell membranes to treat solid tumors with reduced toxicity to healthy tissue. The company's lead program, PDC-1, is designed to treat colorectal and pancreatic cancer and is advancing toward clinical candidate selection.
Investors · 2
Frequently asked questions
- What does Newpathmolecular do?
- New Path Molecular develops drug conjugates targeting phosphatidylserine on cancer cell membranes to treat solid tumors with reduced toxicity to healthy tissue. The company's lead program, PDC-1, is designed to treat colorectal and pancreatic cancer and is advancing toward clinical candidate selection.
- Who are Newpathmolecular's investors?
- Newpathmolecular's investors include Deepbridge Capital, Oxford Investment Opportunity Network (OION).